Inoviq Aktie
Marktkapitalisierung
25,48 Mio. AU$
25,48 Mio. AU$
Streubesitz
57,27%
KGV
-5,59
Index-Zuordnung
-
Inoviq Ltd Unternehmensprofil
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
Vorstand
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., M.B.A., M.R.C.V.S.
Geschäftsführender Direktor
Herr Mark Edwards BACC, C.A.
CFO & Sekretär der Gesellschaft
Dr. Rebecca Lim
Wissenschaftlicher Leiter
Dr. Emma Ball B.Sc., M.B.A., Ph.D.
Kaufmännischer Leiter
Aktionärsstruktur
79,548%
Freefloat
70,75%
Individuelle Aktionäre
8,798%
Institutionelle Aktionäre
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | Australien |
| Währung | AUD |
| Branche | Diagnostik & Forschung |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway